Deep Value: cash covers more than 100% of the stock price

This company holds roughly $6M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Curis

CRIS

Biotechnology · Healthcare

Price

$1.58

-0.03 (-1.86%)

Market Cap

$3.1M

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Based on the IPO prospectus (annual filing). This score will refine automatically once the company reports its first quarters.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+187.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 229K (2021) → 658K (2025)

Winston Score History

The full picture

Curis is a small biotechnology company that discovers and develops drugs to treat cancer. Its main product is vismodegib, a pill that treats a type of skin cancer called basal cell carcinoma. Curis partnered with Genentech (a division of Roche) to develop and sell vismodegib, which is marketed under the brand name Erivedge.

Curis makes most of its money through royalties paid by Genentech on sales of Erivedge, rather than selling drugs directly to patients itself. The company is based in the United States and is very small, with a market cap near zero. Its near-100% gross margin reflects the royalty model, but its deeply negative operating margin shows it spends far more on research than it earns. The biggest risk Curis faces is its heavy dependence on a single royalty stream, meaning any decline in Erivedge sales or changes to its Genentech agreement could seriously hurt the business.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+70.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$28M/ year

↓ Declining (-27% vs prior year)

299.2% of revenue

16.6x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

18.3%ownership

Insiders own a meaningful stake in the company

Cash Runway

~2 months

$6M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Curis has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

99.5%

Premium pricing power — 99.5% gross margin

Profit after running costs

Operating Margin

-348.4%

Losing money on operations — -348.4%

Return on the money invested

ROCE

-494.6%

Weak — -494.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-13.4%

Shrinking sales (-13.4% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-288.1%

Burning cash (-288.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.22

Conservative — low debt load (0.22)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial